Thanks for starting this thread. I have posted this before in...

Thanks for starting this thread. I have posted this before in 2018 after visiting FLC at Singapore's International Water Week Exhibition. Reiterating what I shared on this forum, I still think Aspiral is a beach head, a path finder to put SUBRE onto China's retrofit market. I think that will put FLC onto a different growth path.

https://www.fluencecorp.com/first-subre-contract-win/

Henry said it here, and I quote, “We estimate that Europe alone potentially constitutes a nearly US$2 billion market opportunity for SUBRE, with even larger market potential in the USA and China, as regulations regarding total nitrogen content in treated effluent are becoming much stricter. We are already in discussion with some of our China partners regarding SUBRE deployments in China. Therefore, we can leverage our existing MABR strategic partnerships to accelerate growth, expand our product range in China and other global markets and strengthen our position as a provider of multi-faceted water treatment solutions. The launch of SUBRE demonstrates Fluence’s ongoing innovation, which will continue to improve its positioning and maintain its leadership in markets it is addressing.” (Emphasis mine).

Reposting this now as a reminder for all.